Novo Nordisk A/S (NVO) announced Tuesday that it will lower the list price or wholesale acquisition cost (WAC), Wegovy (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus (semaglutide) tablets 7 mg or 14 mg to $675, effective January 1, 2027.
This represents price reduction of approximately 50% and 35% for Wegovy and Ozempic, respectively, from the current list price. Wegovy, Ozempic, and Rybelsus deliver powerful efficacy in addition to offering a broad range of indications unlike other GLP-1s.
The price cut will help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. It will also address access barriers to these innovative medicines, especially for patients whose out-of-pocket costs are linked to list price.
These changes in list price do not have an impact on direct-to-patient, self-pay prices.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.